Brief: Third Harmonic Bio Announces Next-Generation Oral Kit Inhibitor Product Candidate
25/07/2023 15:41
July 25 (Reuters) - Third Harmonic Bio Inc THRD.O :
* THIRD HARMONIC BIO ANNOUNCES NEXT-GENERATION ORAL KIT
INHIBITOR
PRODUCT CANDIDATE THB335
* THIRD HARMONIC BIO INC - U.S. IND APPLICATION FILING AND
INITIATION OF CLINICAL TRIALS OF THB335 PLANNED FORTHE FIRST
HALF OF 2024
* THIRD HARMONIC BIO INC - THB001 SHOWED EVIDENCE OF PD
ACTIVITY,
CLINICAL BENEFIT IN DISCONTINUED PHASE 1B STUDY IN CHRONIC
INDUCIBLE URTICARIA
Source text for Eikon: ID:nGNX7SbYW7
Further company coverage: THRD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Third Harmonic Bio
See all newsThird Harmonic Bio Inc reports results for the quarter ended March 31 - Earnings Summary
Third Harmonic Bio Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Third Harmonic Bio Announces Plan Of Liquidation And Dissolution
Third Harmonic Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Third Harmonic Bio Q4 Net Income USD -13.1 Million